Trigeminal neuralgia (TN), also known as tic douloureux, is a common and potentially disabling pain syndrome, the precise pathophysiology of which remains obscure. This condition has been known to drive patients with trigeminal neuralgia to the brink of suicide. Although neurologic examination findings are normal in patients with the idiopathic variety, the most common type of facial pain neuralgia, the clinical history is distinctive. Although there is general agreement that none of the many existing theories fully explain all known characteristics of TGN pain the bulk of current evidence points to the trigeminal nerve rather than the CNS as the site of generation of TGN pain. More specifically, the existing evidence suggests that a slowly evolving process, whether a compression exerted on the nerve by a blood vessel or tumour or alteration of neural functions by an MS plaque at the level of the dorsal root entry zone, leads to increased excitability in some of the trigeminal afferents and subsequently to typical TGN. Patients may find immediate and satisfying relief with one medication, typically carbamazepine. However, because this disorder may remit spontaneously after 6-12 months, patients may elect to discontinue their medication in the first year following the diagnosis. Most must restart medication in the future. Furthermore, over the years, they may require a second or third drug to control breakthrough episodes and finally may need surgical intervention. Belgium people around 96,992 among the total population are suffering from this disease that is 1.58% of the population effected.